石藥集團(01093.HK)與Flame Biosciences訂立策略合作
石藥集團(01093.HK)公布,附屬NovaRock與美國的創新製藥公司Flame Biosciences訂立策略合作及許可協議。據此,Flame Biosciences獲授予在大中華(包括中國、香港、澳門及台灣)以外地區開發、製造及商業化其全人源抗Claudin 18.2單克隆抗體(NBL-015)的獨家權利。同時,雙方亦將合作發現及臨床前開發兩款新型雙特異性抗體,所有開支由Flame Biosciences承擔,並其後授予Flame Biosciences在區域開發、製造及商業化該兩款新型雙特異性抗體的獨家權利。
NovaRock將收取750萬美元的首付款,並有權在達成開發里程碑事件的條件下收取最多1.73億美元的開發里程碑款項,亦有權在達成銷售里程碑事件的條件下收取最多4.6億美元銷售里程碑款項,及按許可產品於區域的銷售淨額的若干百分比收取提成。
NBL-015是一種全人源抗Claudin 18.2單克隆抗體,有望成為治療胰腺癌和胃癌的同類最佳靶向藥物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
![](/hk/assets/image/code.84ab0b.png)
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.